NASDAQ:NERV

Minerva Neurosciences - NERV Stock Forecast, Price & News

$9.23

-0.29 (-3.05%)

(As of 09/30/2022 12:00 AM ET)

Add

Compare

Today's Range: $9.09
▼
$10.28
50-Day Range: $2.53
▼
$13.17
52-Week Range: $2.51
▼
$15.27

Volume: 625,946 shs
Average Volume: 912,135 shs
Market Capitalization: $49.29 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $24.00

Minerva Neurosciences MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 160.0% Upside
$24.00 Price Target
Short Interest: Healthy
23.96% of Float Sold Short
Dividend Strength: N/A
Sustainability: -0.75
Upright™ Environmental Score
News Sentiment: 0.63
Based on 9 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($5.74) to ($5.99) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.19 out of 5 stars

Medical Sector

500th out of 1,095 stocks

Pharmaceutical Preparations Industry

233rd out of 547 stocks

3.5

Analyst's Opinion

Consensus Rating
Minerva Neurosciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $24.00, Minerva Neurosciences has a forecasted upside of 160.0% from its current price of $9.23.
Amount of Analyst Coverage
Minerva Neurosciences has received no research coverage in the past 90 days.

4.0

Short Interest

Percentage of Shares Shorted
23.96% of the float of Minerva Neurosciences has been sold short.
Short Interest Ratio / Days to Cover
Minerva Neurosciences has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Minerva Neurosciences has recently decreased by 31.88%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Minerva Neurosciences does not currently pay a dividend.
Dividend Growth
Minerva Neurosciences does not have a long track record of dividend growth.

4.6

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Minerva Neurosciences has received a 71.93% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is mostly driven by its "Preclinical research services for mental health", "Preclinical research services for physical health", and "Clinical research services for Parkinsonism" products. See details.
Environmental Sustainability
The Environmental Impact score for Minerva Neurosciences is -0.75.

2.0

News and Social Media Coverage

News Sentiment
Minerva Neurosciences has a news sentiment score of 0.63. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.84 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 9 news articles for Minerva Neurosciences this week, compared to 1 article on an average week.
Search Interest
Only 33 people have searched for NERV on MarketBeat in the last 30 days. This is a decrease of -49% compared to the previous 30 days.
MarketBeat Follows
Only 9 people have added Minerva Neurosciences to their MarketBeat watchlist in the last 30 days. This is a decrease of -55% compared to the previous 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Minerva Neurosciences insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 5.50% of the stock of Minerva Neurosciences is held by insiders.
Percentage Held by Institutions
51.31% of the stock of Minerva Neurosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Minerva Neurosciences are expected to decrease in the coming year, from ($5.74) to ($5.99) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Minerva Neurosciences is -1.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Minerva Neurosciences is -1.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Minerva Neurosciences has a P/B Ratio of 6.19. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Minerva Neurosciences (NASDAQ:NERV) Stock

Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone for the treatment of schizophrenia; and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. Minerva Neurosciences, Inc. has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. The company was formerly known as Cyrenaic Pharmaceuticals, Inc. and changed its name to Minerva Neurosciences, Inc. in 2013. Minerva Neurosciences, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.

Receive NERV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Minerva Neurosciences and its competitors with MarketBeat's FREE daily newsletter.

NERV Stock News Headlines

September 12, 2022 | pricetargets.com

Its Been A Slow, But Promising Climb for Minerva Neurosciences

September 30, 2022 | americanbankingnews.com

Minerva Neurosciences (NASDAQ:NERV) Upgraded to "Hold" by StockNews.com

September 28, 2022 | msn.com

How Is The Market Feeling About Minerva Neurosciences?

September 28, 2022 | finance.yahoo.com

Minerva University Launches Graduate Certificate in Decision Analysis and Graduate Immersion Opportunities

September 26, 2022 | 247wallst.com

Leading Indicators Say Minerva Neuro Could Be Ripe For Another Short Squeeze

September 26, 2022 | markets.businessinsider.com

10 Short Squeeze Candidates That May Soar: Minerva Neurosciences, FaZe, Getty Images And More

September 9, 2022 | finanznachrichten.de

Minerva Neurosciences, Inc: Minerva Neurosciences Announces Listing Transfer to Nasdaq Capital Market

September 9, 2022 | finance.yahoo.com

Minerva Neurosciences Announces Listing Transfer to Nasdaq Capital Market

August 25, 2022 | seekingalpha.com

Minerva Neurosciences rises 42% after Steven Cohen firm discloses large stake

August 25, 2022 | morningstar.com

Minerva Neurosciences Shares Leap 72% After Point72 Stake Disclosed

August 25, 2022 | stocknews.com

Minerva Neurosciences up More Than 100% This Week, but Is It a Better Pick Than Vertex Pharma?

August 23, 2022 | finance.yahoo.com

Minerva (NERV) Submits NDA for Schizophrenia Candidate, Stock Up

August 22, 2022 | marketwatch.com

Minerva Neurosciences Shares Rise 47% After NDA for Roluperidone

August 22, 2022 | finance.yahoo.com

Minerva Neurosciences Submits New Drug Application to FDA for Roluperidone for the Treatment of Negative Symptoms in Patients with Schizophrenia

August 12, 2022 | finance.yahoo.com

Here's Why Minerva Neurosciences (NERV) Could be Great Choice for a Bottom Fisher

August 11, 2022 | msn.com

Minerva High School to add seven new members to athletic hall of fame

August 9, 2022 | msn.com

Minerva Neurosciences: Q2 Earnings Insights

August 9, 2022 | finanznachrichten.de

Minerva Neurosciences, Inc: Minerva Neurosciences Reports Second Quarter 2022 Financial Results and Business Updates

August 9, 2022 | finance.yahoo.com

Minerva Neurosciences Reports Second Quarter 2022 Financial Results and Business Updates

June 22, 2022 | finance.yahoo.com

Here's Why We're Not Too Worried About Minerva Neurosciences' (NASDAQ:NERV) Cash Burn Situation

June 21, 2022 | marketwatch.com

Minerva Neurosciences Shares Slip After Reverse Split >NERV

May 6, 2022 | finanznachrichten.de

Minerva Neurosciences, Inc: Minerva Neurosciences Reports First Quarter 2022 Financial Results and Business Updates

May 4, 2022 | seekingalpha.com

Minerva Neurosciences GAAP EPS of -$0.23 misses by $0.05

May 4, 2022 | finance.yahoo.com

Minerva Neurosciences Reports First Quarter 2022 Financial Results and Business Updates

May 3, 2022 | finance.yahoo.com

Minerva Neurosciences, Inc. (NERV)

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive NERV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Minerva Neurosciences and its competitors with MarketBeat's FREE daily newsletter.

NERV Company Calendar

Last Earnings: 8/09/2022
Today: 10/02/2022
Next Earnings (Estimated): 11/14/2022
Fiscal Year End: 12/31/2022

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:NERV
CUSIP: N/A
CIK: 1598646
Web: www.minervaneurosciences.com
Phone: (617) 600-7373
Fax: N/A
Employees: 9
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $24.00
High Stock Price Forecast: $24.00
Low Stock Price Forecast: $24.00
Forecasted Upside/Downside: +160.0%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($9.23)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-49,910,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -485.51%
Return on Assets: -42.15%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 14.68
Quick Ratio: 14.68

Sales & Book Value

Annual Sales: $41.18 million
Price / Sales: 1.20
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.49 per share
Price / Book: 6.19

Miscellaneous

Outstanding Shares: 5,340,000
Free Float: 5,046,000
Market Cap: $49.29 million
Optionable: Optionable
Beta: -0.21

Key Executives

Dr. Remy Luthringer Ph.D. (Age 61)
Exec. Chairman & CEO
Comp: $1.19M

Mr. Geoffrey Robin Race F.C.M.A. (Age 61)
FCMA, M.B.A., MBA, Pres
Comp: $880.44k

Mr. Frederick W. Ahlholm CPA (Age 56)
CPA, Sr. VP, CFO & Sec.
Comp: $610.68k

Dr. Michael Davidson M.D. (Age 72)
Chief Medical Officer
Comp: $657.47k

Mr. Joseph Reilly (Age 47)
Sr. VP & COO

Mr. William B. Boni (Age 70)
VP of Investor Relations & Corp. Communications

Dr. Ramana Kuchibhatla Ph.D.
Sr. VP and Head of R&D

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

NERV Stock - Frequently Asked Questions

Should I buy or sell Minerva Neurosciences stock right now?: 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Minerva Neurosciences in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" NERV shares.
View NERV analyst ratings or view top-rated stocks.
What is Minerva Neurosciences' stock price forecast for 2022?: 1 Wall Street research analysts have issued 1 year price targets for Minerva Neurosciences' stock. Their NERV share price forecasts range from $24.00 to $24.00. On average, they predict the company's share price to reach $24.00 in the next year. This suggests a possible upside of 160.0% from the stock's current price.
View analysts price targets for NERV or view top-rated stocks among Wall Street analysts.
How have NERV shares performed in 2022?: Minerva Neurosciences' stock was trading at $6.4080 at the start of the year. Since then, NERV stock has increased by 44.0% and is now trading at $9.23.
View the best growth stocks for 2022 here.
When is Minerva Neurosciences' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, November 14th 2022.
View our NERV earnings forecast.
How were Minerva Neurosciences' earnings last quarter?: Minerva Neurosciences, Inc. (NASDAQ:NERV) issued its earnings results on Tuesday, August, 9th. The biopharmaceutical company reported ($1.63) EPS for the quarter, topping the consensus estimate of ($1.84) by $0.21.

When did Minerva Neurosciences' stock split?: Minerva Neurosciences's stock reverse split on Tuesday, June 21st 2022. The 1-8 reverse split was announced on Tuesday, June 21st 2022. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, June 21st 2022. An investor that had 100 shares of stock prior to the reverse split would have 13 shares after the split.
What other stocks do shareholders of Minerva Neurosciences own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Minerva Neurosciences investors own include Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), PTC Therapeutics (PTCT), Immunomedics (IMMU), VBI Vaccines (VBIV), Dynavax Technologies (DVAX), Gilead Sciences (GILD), Moderna (MRNA), T2 Biosystems (TTOO) and Advanced Micro Devices (AMD).
What is Minerva Neurosciences' stock symbol?: Minerva Neurosciences trades on the NASDAQ under the ticker symbol "NERV."
How do I buy shares of Minerva Neurosciences?: Shares of NERV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Minerva Neurosciences' stock price today?: One share of NERV stock can currently be purchased for approximately $9.23.
How much money does Minerva Neurosciences make?: Minerva Neurosciences (NASDAQ:NERV) has a market capitalization of $49.29 million and generates $41.18 million in revenue each year. The biopharmaceutical company earns $-49,910,000.00 in net income (profit) each year or ($9.23) on an earnings per share basis.
How can I contact Minerva Neurosciences?: Minerva Neurosciences' mailing address is 1601 TRAPELO ROAD SUITE 286, WALTHAM MA, 02451. The official website for the company is www.minervaneurosciences.com. The biopharmaceutical company can be reached via phone at (617) 600-7373 or via email at wboni@minervaneurosciences.com.

This page (NASDAQ:NERV) was last updated on 10/2/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Minerva Neurosciences - NERV Stock Forecast, Price & News

Minerva Neurosciences MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows